-
公开(公告)号：US20160009691A1
公开(公告)日：2016-01-14
申请号：US14770759
申请日：2014-03-06
Applicant: DART NEUROSCIENCE (CAYMAN) LTD.
Inventor： Venkataiah Bollu , James Breitenbucher , Alan Kaplan , Robert Lemus , Andrew Lindstrom , Troy Vickers , Michael Weinhouse , Mark Edward Wilson , James Zapf
IPC: C07D403/06 , C07D401/06 , C07D239/34 , C07D213/64 , C07D405/12 , C07D417/06 , A61K51/04 , C07D401/14
CPC classification number: C07D403/06 , A61K51/0459 , C07D213/64 , C07D213/73 , C07D213/74 , C07D213/81 , C07D239/34 , C07D241/18 , C07D401/06 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/06 , C07D409/14 , C07D413/06 , C07D417/06
Abstract: The invention provides a chemical entity of Formula (I), and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting PDE4, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a CNS disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating peripheral disorders, including inflammatory and renal disorders.
Abstract translation: 本发明提供式（I）的化学实体和包含这些化学实体的组合物; 制作方法; 并在广泛的方法中使用，包括代谢和反应动力学研究，检测和成像技术以及放射性治疗; 和治疗方法，包括抑制PDE4，增强神经元可塑性，治疗神经障碍，提供神经保护，治疗与CNS病症相关的认知障碍，提高认知和运动训练的效率，提供神经复发和神经康复，提高非人类动物的效率 训练方案和治疗外周疾病，包括炎症和肾脏疾病。
-
公开(公告)号：US20200024259A1
公开(公告)日：2020-01-23
申请号：US16424366
申请日：2019-05-28
Applicant: DART NEUROSCIENCE (CAYMAN) LTD.
Inventor： Venkataiah Bollu , James Breitenbucher , Alan Kaplan , Robert Lemus , Andrew Lindstrom , Troy Vickers , Michael Weinhouse , Mark E. Wilson , James Zapf
IPC: C07D403/06 , C07D401/06 , C07D405/14 , C07D413/06 , C07D417/06 , C07D409/14 , C07D213/73 , C07D213/74 , C07D213/81 , C07D213/64 , C07D241/18 , C07D401/14 , C07D405/12 , C07D409/06 , A61K51/04 , C07D239/34
Abstract: The invention provides a chemical entity of Formula (I), and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting PDE4, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a CNS disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating peripheral disorders, including inflammatory and renal disorders.
-
公开(公告)号：US09573937B2
公开(公告)日：2017-02-21
申请号：US14720321
申请日：2015-05-22
Applicant: Dart Neuroscience (Cayman) Ltd.
Inventor： Venkataiah Bollu , James Breitenbucher , Alan Kaplan , Robert Lemus , Andrew Lindstrom , Troy Vickers , Mark Wilson , James Zapf
IPC: C07D241/18 , C07D403/06 , C07D401/06 , C07D401/14 , C07D213/64 , C07D405/12 , C07D417/06 , C07D405/14 , C07D413/06 , C07D409/14 , C07D409/06 , C07D213/73 , C07D213/74 , C07D213/81 , A61K51/04 , C07D239/34
CPC classification number: C07D403/06 , A61K51/0459 , C07D213/64 , C07D213/73 , C07D213/74 , C07D213/81 , C07D239/34 , C07D241/18 , C07D401/06 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/06 , C07D409/14 , C07D413/06 , C07D417/06
Abstract: The invention provides a chemical entity of Formula (I) wherein R1, R2, R3, R4, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting PDE4, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a CNS disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating peripheral disorders, including inflammatory and renal disorders.
Abstract translation: 本发明提供式（I）的化学实体，其中R 1，R 2，R 3，R 4，Y和Z具有本文所述的任何值，以及包含这些化学实体的组合物; 制作方法; 并在广泛的方法中使用，包括代谢和反应动力学研究，检测和成像技术以及放射性治疗; 和治疗方法，包括抑制PDE4，增强神经元可塑性，治疗神经障碍，提供神经保护，治疗与CNS病症相关的认知障碍，提高认知和运动训练的效率，提供神经复发和神经康复，提高非人类动物的效率 训练方案和治疗外周疾病，包括炎症和肾脏疾病。
-
公开(公告)号：US09120770B2
公开(公告)日：2015-09-01
申请号：US14204934
申请日：2014-03-11
Applicant: DART NEUROSCIENCE (CAYMAN) LTD.
Inventor： Venkataiah Bollu , James Breitenbucher , Alan Kaplan , Robert Lemus , Andrew Lindstrom , Troy Vickers , Mark E. Wilson , James Zapf
IPC: C07D409/06 , C07D401/06 , C07D405/14 , C07D413/06 , C07D417/06 , C07D213/64 , C07D241/18 , C07D401/14 , C07D403/06 , C07D405/12
CPC classification number: C07D403/06 , A61K51/0459 , C07D213/64 , C07D213/73 , C07D213/74 , C07D213/81 , C07D239/34 , C07D241/18 , C07D401/06 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/06 , C07D409/14 , C07D413/06 , C07D417/06
Abstract: The invention provides a chemical entity of Formula (I) wherein R1, R2, R3, R4, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting PDE4, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a CNS disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating peripheral disorders, including inflammatory and renal disorders.
-
公开(公告)号：US09040692B2
公开(公告)日：2015-05-26
申请号：US14205033
申请日：2014-03-11
Applicant: DART NEUROSCIENCE (Cayman), LTD.
Inventor： Venkataiah Bollu , James Breitenbucher , Alan Kaplan , Robert Lemus , Andrew Lindstrom , Troy Vickers , Mark E. Wilson , James Zapf
IPC: C07D401/06 , C07D405/14 , C07D413/06 , C07D417/06 , C07D409/06 , C07D213/64 , C07D241/18 , C07D401/14 , C07D403/06 , C07D405/12
CPC classification number: C07D403/06 , A61K51/0459 , C07D213/64 , C07D213/73 , C07D213/74 , C07D213/81 , C07D239/34 , C07D241/18 , C07D401/06 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/06 , C07D409/14 , C07D413/06 , C07D417/06
Abstract: The invention provides a chemical entity of Formula (I) wherein R1, R2, R3, R4, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting PDE4, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a CNS disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating peripheral disorders, including inflammatory and renal disorders.
Abstract translation: 本发明提供式（I）的化学实体，其中R 1，R 2，R 3，R 4，Y和Z具有本文所述的任何值，以及包含这些化学实体的组合物; 制作方法; 并在广泛的方法中使用，包括代谢和反应动力学研究，检测和成像技术以及放射性治疗; 和治疗方法，包括抑制PDE4，增强神经元可塑性，治疗神经障碍，提供神经保护，治疗与CNS病症相关的认知障碍，提高认知和运动训练的效率，提供神经复发和神经康复，提高非人类动物的效率 训练方案和治疗外周疾病，包括炎症和肾脏疾病。
-
Patent Agency Ranking
![Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as PDE2 inhibitors](/abs-image/US/2021/11/30/US11186582B2/abs.jpg.150x150.jpg)
公开(公告)号：US11186582B2
公开(公告)日：2021-11-30
申请号：US16694869
申请日：2019-11-25
Applicant: DART NEUROSCIENCE (CAYMAN) LTD.
Inventor： James Breitenbucher , Graeme Freestone , Laurent Gomez , Robert Lemus , Kiev Ly , Margaret McCarrick , William Vernier , Troy Vickers
IPC: C07D487/04 , A61P25/28 , C07D519/00 , A61P25/24 , A61P25/18 , A61P25/22 , A61K31/519
Abstract: The invention provides a chemical entity of Formula (I): wherein R1, R2, X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods as disclosed herein, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.
-
![SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS](/abs-image/US/2020/03/26/US20200095256A1/abs.jpg.150x150.jpg)
公开(公告)号：US20200095256A1
公开(公告)日：2020-03-26
申请号：US16694869
申请日：2019-11-25
Applicant: DART NEUROSCIENCE (CAYMAN) LTD.
Inventor： James Breitenbucher , Graeme Freestone , Laurent Gomez , Robert Lemus , Kiev Ly , Margaret McCarrick , William Vernier , Troy Vickers
IPC: C07D487/04 , C07D519/00 , A61P25/28 , A61K31/519
Abstract: The invention provides a chemical entity of Formula (I): wherein R1, R2, X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods as disclosed herein, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.
-
![SUBSTITUTED 5-METHYL-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-2-AMINE COMPOUNDS AS PDE2 INHIBITORS](/abs-image/US/2018/10/04/US20180282338A1/abs.jpg.150x150.jpg)
8.发明申请公开(公告)号：US20180282338A1
公开(公告)日：2018-10-04
申请号：US15524586
申请日：2015-11-03
Applicant: DART NEUROSCIENCE (CAYMAN) LTD.
Inventor： Amy Lynn Allan , James Breitenbucher , Laurent Gomez , Terence Patrick Keenan , Robert Lemus , Kiev Ly , Tami Jo Marrone
IPC: C07D487/04 , A61P25/00
CPC classification number: C07D487/04 , A61P25/00
Abstract: The invention provides a chemical entity of Formula (I): (I), wherein R1, R2, R3, and R4, have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.
-
![SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS](/abs-image/US/2018/06/28/US20180179216A1/abs.jpg.150x150.jpg)
公开(公告)号：US20180179216A1
公开(公告)日：2018-06-28
申请号：US15905672
申请日：2018-02-26
Applicant: DART NEUROSCIENCE (CAYMAN) LTD.
Inventor： James Breitenbucher , Graeme Freestone , Laurent Gomez , Robert Lemus , Kiev Ly , Margaret McCarrick , William Vernier , Troy Vickers
IPC: C07D487/04 , C07D519/00
CPC classification number: C07D487/04 , A61K31/519 , A61P25/28 , C07D519/00
Abstract: The invention provides a chemical entity of Formula (I): wherein R1, R2, X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods as disclosed herein, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.
-
公开(公告)号：US20150329500A1
公开(公告)日：2015-11-19
申请号：US14720321
申请日：2015-05-22
Applicant: Dart Neuroscience (Cayman) Ltd.
Inventor： Venkataiah Bollu , James Breitenbucher , Alan Kaplan , Robert Lemus , Andrew Lindstrom , Troy Vickers , Mark Wilson , James Zapf
IPC: C07D241/18 , C07D401/06 , C07D401/14 , C07D409/14 , C07D405/12 , C07D417/06 , C07D405/14 , C07D413/06 , C07D403/06 , C07D213/64
CPC classification number: C07D403/06 , A61K51/0459 , C07D213/64 , C07D213/73 , C07D213/74 , C07D213/81 , C07D239/34 , C07D241/18 , C07D401/06 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/06 , C07D409/14 , C07D413/06 , C07D417/06
Abstract: The invention provides a chemical entity of Formula (I) wherein R1, R2, R3, R4, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting PDE4, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a CNS disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating peripheral disorders, including inflammatory and renal disorders.
Abstract translation: 本发明提供式（I）的化学实体，其中R 1，R 2，R 3，R 4，Y和Z具有本文所述的任何值，以及包含这些化学实体的组合物; 制作方法; 并在广泛的方法中使用，包括代谢和反应动力学研究，检测和成像技术以及放射性治疗; 和治疗方法，包括抑制PDE4，增强神经元可塑性，治疗神经障碍，提供神经保护，治疗与CNS病症相关的认知障碍，提高认知和运动训练的效率，提供神经复发和神经康复，提高非人类动物的效率 训练方案和治疗外周疾病，包括炎症和肾脏疾病。
-
-
-
-
-
-
-
-
-
Search Results
14
records
(took 0.034 seconds)
